Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
+0.16%
$10.09
70% positive prob.
5-Day Prediction
+6.64%
$10.74
70% positive prob.
20-Day Prediction
+11.47%
$11.22
67% positive prob.
| Quarter | Signal | 1D Return | 5D Return | 20D Return | Confidence | Actual 5D |
|---|---|---|---|---|---|---|
| Q3 2026 | BUY | +0.16% | +6.64% | +11.47% | 40.7% | Pending |
| Q2 2026 | SELL | -6.48% | -9.38% | -4.68% | 100.0% | Pending |
| Q1 2026 | SELL | -7.83% | -9.97% | -7.51% | 100.0% | -6.45% |
| Q4 2025 | BUY | -0.13% | +11.94% | +22.42% | 100.0% | -1.50% |
SEC 8-K filings with transcript text
Nov 10, 2026 · 41% conf.
1D
+0.16%
$10.09
Act: +0.65%
5D
+6.64%
$10.74
20D
+11.47%
$11.22
2 mass-ex99d1.htm
Exhibit 99.1
908 Devices Reports Third Quarter 2026 Financial Results and Achieves Record Revenue
Revenue increased 35% compared to prior year
Raises low end of 2026 revenue outlook
BURLINGTON, Mass. – November 10, 2026 – 908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety, and defense tech applications, today reported financial results for the quarter ended September 30, 2026.
"We had a strong third quarter, driven by our FTIR portfolio, with revenue growing 35% year-over-year to $19 million and device shipments reaching a new company record,” said Kevin J. Knopp, CEO and Co-founder. "Our proven platforms are winning orders across the globe as customers accelerate efforts to modernize their detection capabilities and stay ahead of an evolving threat landscape. NIRLab is also gaining traction, both in unit volumes and pipeline, as we build a growing base of connected, recurring revenue. With continued operational discipline and healthy customer funding supporting demand, we are well positioned as we head toward the end of the year.”
Recent Highlights
●Revenue of $19.0 million for the third quarter of 2026, increasing 35% year-over-year
●Recurring revenue of $5.1 million, representing 27% of total revenues for the quarter
●Gross margin of 53% and adjusted gross margin of 58% for the third quarter of 2026
●Net loss from continuing operations of $4.6 million and Adjusted EBITDA loss of $1.7 million for the third quarter of 2026
●Ended the quarter with a strong balance sheet, with a cash position of $99.1 million
●Shipped approximately 100 NIRLab devices in the first full quarter following the acquisition
Third Quarter 2026 Financial Results
Revenue was $19.0 million for the three months ended September 30, 2026, a 35% increase over the prior year period, driven by an increase in product revenue for FTIR devices and the addition of NIRLab revenue. The installed base grew 26% year-over-year to 4,409 devices, with 308 devices placed during the third quarter, a new company record. Recurring revenue represented 27% of total revenues in the quarter.
Gross profit was $10.0 million for the third quarter of 2026, compared to $7.4 million for the corresponding period in the prior year. GAAP gross margin was 53% as compared to 53% for the corresponding prior year period. Adjusted gross profit was $10.9 million for the third quarter of 2026, compared to $8.1 million for the corresponding period in the prior year. Adjusted gross margin was 58%, as compared to 58% for the corresponding prior year period.
Operating expenses were $15.5 million for the third quarter of 2026, compared to $23.7 million for the corresponding prior year period. The $8.2 million decrease was primarily driven by an $11.0 million noncash reduction in expense related to the change in fair value of contingent consideration, partially offset by a $2.8 million increase in selling, general and administrative expenses.
Net loss from continuing operations was $4.6 million for the third quarter of 2026, compared to a net loss from continuing operations of $14.9 million for the corresponding prior year period. Adjusted EBITDA was a loss of $1.7 million for the third quarter of 2026, compared to a loss of $1.8 million for the corresponding period in the prior year.
Net loss attributable to common stockholders was $4.6 million for the third quarter of 2026, compared to $15.0 million for the corresponding prior year period.
Cash, cash equivalents and marketable securities were $99.1 million as of September 30, 2026, with no debt outstanding.
2026 Guidance
908 Devices updates its full year revenue guidance range to $68.5 million to $70.0 million (from $68.0 million to $70.0 million previously), raising the low end of the range and representing 22% to 25% growth compared to 2025 revenue.
Webcast Information
908 Devices will host a conference call to discuss the third quarter 2026 financial results before market open on Tuesday, November 10, 2026 at 8:30 am Eastern Time. A webcast of the conference call can be accessed in the Investor Relations section of 908devices.com. The webcast will be archived and available for replay for at least 90 days after the event.
About 908 Devices
908 Devices is revolutionizing chemical analysis with its simple handheld devices, addressing life-altering applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers in vital health, safety and defense tech applications, addressing the fentanyl and illicit drug crisis, toxic carcinogen exposure, and global security threats. The Company designs and manufactures innovative products that bring together the power of complementary analytical technologies, software automation, and machine learnin
Aug 11, 2026 · 100% conf.
1D
-6.48%
$9.25
Act: +1.31%
5D
-9.38%
$8.96
20D
-4.68%
$9.43
2 mass-20260811xex99d1.htm
Exhibit 99.1
908 Devices Reports Second Quarter 2026 Financial Results and Raises Low End of 2026 Revenue Outlook
Revenue increased 23% compared to prior year
Updated full year 2026 outlook reflects 21% to 25% year-over-year growth
BURLINGTON, Mass. – August 11, 2026 – 908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety, and defense tech applications, today reported financial results for the quarter ended June 30, 2026.
“We delivered another strong quarter, growing revenue 23% year-over-year, while narrowing our Adjusted EBITDA loss by more than half compared to a year ago,” said Kevin J. Knopp, CEO and Co-founder. “Our momentum with U.S. state and local customers remained particularly strong, representing more than half of our revenue, as agencies modernize to address today's threats and hazards. Our newest FTIR product, VipIR, is leading that charge, and we surpassed our 100th unit shipped since launch. With the same commercial channel behind that momentum, we are now introducing NIRLab to the U.S. market. In just our first 60 days since deal close, we have engaged hundreds of prospects nationwide across more than 30 agencies. With a robust pipeline of opportunities, we are confident in our team's ability to deliver, and we remain committed to the disciplined execution of our strategy.”
Recent Highlights
●Revenue of $16.1 million for the second quarter of 2026, increasing 23% year-over-year
●Recurring revenue was $4.9 million, representing 31% of total revenues for the quarter
●Gross margin was 52% and adjusted gross margin was 57% for the second quarter of 2026, an 85-basis point improvement in adjusted gross margin compared to the second quarter of 2025
●Net loss from continuing operations was $11.9 million and Adjusted EBITDA loss was $1.9 million for the second quarter of 2026, a reduction of more than 50% year-over-year
●Ended the quarter with a strong balance sheet, with a cash position of $101.5 million
●Shipped more than 35 VipIR chemical identification devices in the quarter, including 18 units to a major South Asia law enforcement agency
●Subsequent to quarter end, secured a $6 million ProtectIR order from a corrections agency in the Asia-Pacific region, further supporting our second-half revenue outlook
Second Quarter 2026 Financial Results
Revenue was $16.1 million for the three months ended June 30, 2026, a 23% increase over the prior year period, driven by an increase in product revenue for VipIR and the addition of NIRLab revenue. The installed base grew 23% year-over-year to 4,101 devices, with 198 devices placed during the second quarter. Recurring revenue represented 31% of total revenues in the quarter.
Gross profit was $8.3 million for the second quarter of 2026, compared to $6.4 million for the corresponding period in the prior year. GAAP gross margin was 52% as compared to 49% for the corresponding prior year period. Adjusted gross profit was $9.2 million for the second quarter of 2026, compared to $7.3 million for the corresponding period in the prior year. Adjusted gross margin was 57%, as compared to 56% for the corresponding prior year period. The increase in adjusted gross margin percentage was primarily driven by higher product revenues, including a shift in channel mix.
Operating expenses were $21.2 million for the second quarter of 2026, compared to $21.5 million for the corresponding prior year period. The decrease of $0.3 million includes a noncash decrease of $0.3 million related to a change in the fair value of the contingent consideration liability.
Net loss from continuing operations was $11.9 million for the second quarter of 2026, compared to a net loss from continuing operations of $12.9 million for the corresponding prior year period. Adjusted EBITDA was a loss of $1.9 million for the second quarter of 2026, compared to a loss of $3.9 million for the corresponding period in the prior year.
Net loss attributable to common stockholders was $11.9 million for the second quarter of 2026, compared to $13.3 million for the corresponding prior year period.
Cash, cash equivalents and marketable securities were $101.5 million as of June 30, 2026, with no debt outstanding. In the second quarter of 2026, $13.5 million of cash and cash equivalents were used for the acquisition of NIRLAB SA and $3.5 million was received from the release of the escrow from the desktop divestiture.
2026 Guidance
908 Devices updates its full year revenue guidance range to $68.0 million to $70.0 million (from $67.0 million to $70.0 million previously), raising the low end of the range and representing 21% to 25% growth compared to 2025 revenue.
Webcast Information
908 Devices will host a conference call to discuss the second quarter 2026 financial results before market open on Tuesday, August
May 6, 2026 · 100% conf.
1D
-7.83%
$7.43
Act: +0.25%
5D
-9.97%
$7.26
Act: -6.45%
20D
-7.51%
$7.45
Act: +9.43%
3 tm2613572d1_ex99-1.htm
Exhibit 99.1
908 Devices Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Outlook
Revenue increased 14% compared to prior year, growth in both Mass Spec and FTIR
Acquired NIRLAB AG, expanding narcotics identification capabilities
Mass. – May 6, 2026 – 908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built
handheld chemical analysis tools for vital health, safety and defense tech applications, today reported financial results for the quarter ended March 31, 2026.
“We delivered a strong start to 2026, achieving 14% revenue growth and meaningful margin expansion,” said Kevin J. Knopp, CEO and Co-founder. “We are also excited to announce the acquisition of NIRLAB AG, a strategic transaction that broadens our reach into the lower-cost, widely-deployable segment of the narcotics detection market while increasing our recurring revenue opportunity through software subscriptions. This transaction reflects our focus on disciplined growth investments as we continue to execute our transformation strategy.”
Recent Highlights
·Revenue of $13.4 million for the first quarter of 2026, increasing 14% year over year
·Recurring revenue was $4.0 million, representing 30% of total revenues for the quarter
·Gross margin was 51% and Adjusted gross margin was 57% for the first quarter of 2026, a 290-basis point improvement in Adjusted gross margin compared to the first quarter of 2025
·Ended the quarter with a strong balance sheet, with a cash position of $111.7 million, consuming less than $1.5 million in the first quarter
·Subsequent to quarter end, acquired NIRLAB AG, bringing complementary drug detection capabilities, more international mix, and a high-retention recurring subscription model
First Quarter 2026 Financial Results
Revenue was $13.4 million for the three months ended March 31, 2026, a 14% increase over the prior year period, driven by an increase in product revenue for mass spec, from an increase in placements, and from a shift in FTIR product mix. OEM and funded partnership revenue was $0.6 million for the current and prior year period. The installed base grew 23% year-over-year to 3,903 devices, with 167 devices placed during the first quarter. Recurring revenue represented 30% of total revenues in the quarter.
Gross profit was $6.9 million for the first quarter of 2026, compared to $5.5 million for the corresponding period in the prior year. GAAP gross margin was 51% as compared to 47% for the corresponding prior year period. Adjusted gross profit was $7.7 million for the first quarter of 2026, compared to $6.4 million for the corresponding period in the prior year. Adjusted gross margin was 57%, as compared to 54% for the corresponding prior year period. The increase in adjusted gross margin percentage was primarily driven by higher product revenues, including a shift in channel mix, along with the favorable impact of consolidated facilities, offset in part by lower service gross margins.
Operating expenses were $19.8 million for the first quarter of 2026, compared to $16.6 million for the corresponding prior year period. The increase of $3.2 million includes a noncash increase of $3.9 million related to a change in the fair value of the contingent consideration liability, and a $0.7 million reduction of operating expenses related to research and development and selling, general, and administrative costs.
Net loss from continuing operations was $12.0 million for the first quarter of 2026, compared to a net loss from continuing operations of $9.8 million for the corresponding prior year period. Adjusted EBITDA was a loss of $2.5 million for the first quarter of 2026, compared to a loss of $4.6 million for the corresponding period in the prior year.
Net loss attributable to common stockholders was $12.0 million for the first quarter of 2026, compared to net income of $43.6 million for the corresponding prior year period. The income was related to the divestiture of our bioprocessing product portfolio which resulted in a gain of $56.6 million, net of transaction costs, and was also offset by a loss from discontinued operations for the first two months of the first quarter of 2025.
Cash, cash equivalents and marketable securities were $111.7 million as of March 31, 2026, with no debt outstanding.
2026 Guidance
908 Devices now expects full year 2026 revenues to be in the range of $67.0 million to $70.0 million, representing 19% to 25% growth compared to 2025 revenue.
Webcast Information
908 Devices will host a conference call to discuss the first quarter 2026 financial results before market open on Wednesday, May 6, 2026 at 8:30 am Eastern Time. A webcast of the conference call can be accessed in the Investor Relations section of 908devices.com. The webcast will be archived and available for replay for at least 90 days after the event.
About 908 Devices
908 Devices is revolutionizi
This page provides 908 Devices Inc. (MASS) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on MASS's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.